poisar

Stocks · News reference

$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today

Aug 10, 2026, 4:15 PMBenzinga Insights

Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 29.76% on an annualized basis producing an average annual return of 41.43%. Currently, Insmed has a market capitalization of $28.82 billion.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

INSM
Source
benzinga
Observed
Aug 10, 2026, 4:15 PM
Checked
Aug 10, 2026, 4:15 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 27, 2026, 6:22 PMNa

    Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

    Liquidia (LQDA) and Insmed (INSM) are compared as commercial-stage biopharmaceutical companies focused on pulmonary hypertension treatments. LQDA shows impressive commercial momentum with Yutrepia generating $170.4M in Q2 sales and achieving four consecutive profitable quarters, but faces heavy reliance on a single product. INSM offers a more diversified portfolio with Brinsupri's strong launch ($1.25-$1.40B 2026 guidance) and established Arikayce revenue, plus a broader pipeline. While LQDA has outperformed INSM significantly this year (106.9% vs -28.5%), analysts recommend INSM as the more compelling long-term choice due to its diversified revenue base and sustainable growth story.

    Read original at zacks-investment-research
    LQDAINSM